TY - JOUR
T1 - Increased burden of comorbidities and risk of cardiovascular death in atrial fibrillation patients in Europe over ten years
T2 - A comparison between EORP-AF pilot and EHS-AF registries
AU - Proietti, Marco
AU - Laroche, Cécile
AU - Nieuwlaat, Robby
AU - Crijns, Harry J.G.M.
AU - Maggioni, Aldo P.
AU - Lane, Deidre A.
AU - Boriani, Guiseppe
AU - Lip, Gregory Y.H.
AU - EORP-AF General Pilot Registry Investigators
AU - Hellum, C. Fragtrup
AU - Mortensen, B.
AU - Joensen, A. M.
AU - Sørensen, B. Ginnerup
AU - Rasmussen, L. H.
AU - Euro Heart Survey on AF Investigators
PY - 2018/9/1
Y1 - 2018/9/1
N2 - Background: In 2002, the European Society of Cardiology conducted the Euro Heart Survey (EHS), while in 2014concluded 1-year follow-up of the EURObservational Research Programme AF (EORP-AF) Pilot Registry. Methods: We analysed differences in clinical profiles, therapeutic approaches and outcomes between these two cohorts after propensity score matching (PSM). Results: After PSM, 5206 patients were analysed. In EORP-AF there were more elderly patients than EHS (p <.001). EORP-AF patients were more burdened with cardiovascular (CV) and non-CV comorbidities, with a higher proportion of patients with high thromboembolic risk. EORP-AF patients used more oral-anticoagulant (OAC) (p <.001). At 1-year follow-up EORP-AF patients had lower risk for thromboembolic and CV events, readmission for AF and other CV reasons (all p <.001), showing conversely a higher risk for CV death (p =.015). Kaplan-Meier curves showed that EORP-AF patients had higher risk for CV death (p <.0001) and all-cause death (p =.0019). Cox regression confirmed that EORP-AF patients were at higher risk for CV death (p =.021). Conclusions: We found significant changes in AF epidemiology over a decade in Europe, with older patients, more burdened with comorbidities. A greater use of OAC was found. Despite a reduction in risk for thromboembolic events, a high risk of CV-related death was still evident.
AB - Background: In 2002, the European Society of Cardiology conducted the Euro Heart Survey (EHS), while in 2014concluded 1-year follow-up of the EURObservational Research Programme AF (EORP-AF) Pilot Registry. Methods: We analysed differences in clinical profiles, therapeutic approaches and outcomes between these two cohorts after propensity score matching (PSM). Results: After PSM, 5206 patients were analysed. In EORP-AF there were more elderly patients than EHS (p <.001). EORP-AF patients were more burdened with cardiovascular (CV) and non-CV comorbidities, with a higher proportion of patients with high thromboembolic risk. EORP-AF patients used more oral-anticoagulant (OAC) (p <.001). At 1-year follow-up EORP-AF patients had lower risk for thromboembolic and CV events, readmission for AF and other CV reasons (all p <.001), showing conversely a higher risk for CV death (p =.015). Kaplan-Meier curves showed that EORP-AF patients had higher risk for CV death (p <.0001) and all-cause death (p =.0019). Cox regression confirmed that EORP-AF patients were at higher risk for CV death (p =.021). Conclusions: We found significant changes in AF epidemiology over a decade in Europe, with older patients, more burdened with comorbidities. A greater use of OAC was found. Despite a reduction in risk for thromboembolic events, a high risk of CV-related death was still evident.
KW - Atrial fibrillation
KW - Epidemiology
KW - Europe
KW - Mortality
KW - Thromboembolic risk
UR - http://www.scopus.com/inward/record.url?scp=85047221052&partnerID=8YFLogxK
U2 - 10.1016/j.ejim.2018.05.016
DO - 10.1016/j.ejim.2018.05.016
M3 - Journal article
SN - 0953-6205
VL - 55
SP - 28
EP - 34
JO - European Journal of Internal Medicine
JF - European Journal of Internal Medicine
ER -